{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:25:05Z","timestamp":1792167905896,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The KEYNOTE-522 clinical trial demonstrated that the addition of pembrolizumab to 8 cycles of neoadjuvant chemotherapy (NAC) improves pathologic complete response (pCR) rates and overall survival in early-stage triple-negative breast cancer (TNBC). However, predictors of response and the benefit of alternative NAC backbones with immunotherapy are not known. This multi-institutional study evaluates clinical factors and treatment variables associated with pCR following NAC plus pembrolizumab in a diverse, real-world cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multi-institution retrospective study analyzed patients with early-stage TNBC diagnosed between July 1, 2021, and December 31, 2023, across three hospital systems. Eligible patients received at least one cycle of NAC and pembrolizumab. Predictors of pCR were assessed using logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 374 patients included, the pCR rate was 61.2%. The cohort was racially and ethnically diverse, with 29.1% of patients identifying as non-White. Almost half (48.4%) had a BMI \u226530, and 70 patients (18.7%) had pre-existing diabetes mellitus.\u00a0Approximately two-thirds (64.4%) completed 8 cycles of neoadjuvant pembrolizumab, while 72.5% completed 8 cycles of NAC. On univariate analysis, age less than 55 years (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03), absence of diabetes mellitus (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03), high tumor grade (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005), the completion of 8 or more cycles of neoadjuvant pembrolizumab (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04) and 8 cycles of NAC (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03) were associated with pCR. There was a trend towards higher pCR rates with the receipt of at least one cycle of anthracycline-cyclophosphamide (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.07). Lack of diabetes mellitus (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03) and high tumor grade (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004) remained significant on multivariate analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study supports the use of KEYNOTE-522 in a diverse, real-world population of patients with early-stage TNBC. Patients with diabetes were less likely to achieve a pCR,\u00a0suggesting a potential impact of glucose metabolism on chemo-immunotherapy resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-026-07984-8","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:22:31Z","timestamp":1779942151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy: a multi-institution study"],"prefix":"10.1007","volume":"217","author":[{"given":"Alexis","family":"LeVee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethania","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Ruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Schmolze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Mortimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"issue":"9","key":"7984_CR1","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L et al (2020) Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 382(9):810\u2013821. https:\/\/doi.org\/10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"issue":"21","key":"7984_CR2","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid Peter C, Javier D, Rebecca et al (2024) Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med 391(21):1981\u20131991. https:\/\/doi.org\/10.1056\/NEJMoa2409932","journal-title":"N Engl J Med"},{"key":"7984_CR3","unstructured":"Keytruda (2025) High-Risk Early-Stage Triple-Negative Breast Cancer. Accessed April 16. https:\/\/www.keytrudahcp.com\/efficacy\/early-stage-triple-negative-breast-cancer\/"},{"issue":"5","key":"7984_CR4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.annonc.2020.01.072","volume":"31","author":"P Schmid","year":"2020","unstructured":"Schmid P, Salgado R, Park YH et al (2020) Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol 31(5):569\u2013581. https:\/\/doi.org\/10.1016\/j.annonc.2020.01.072","journal-title":"Ann Oncol"},{"issue":"8","key":"7984_CR5","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","volume":"30","author":"S Loibl","year":"2019","unstructured":"Loibl S, Untch M, Burchardi N et al (2019) A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol 30(8):1279\u20131288. https:\/\/doi.org\/10.1093\/annonc\/mdz158","journal-title":"Ann Oncol"},{"issue":"1","key":"7984_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41523-022-00500-3","volume":"8","author":"FO Ademuyiwa","year":"2022","unstructured":"Ademuyiwa FO, Gao F, Street CR et al (2022) A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. npj Breast Cancer 8(1):134. https:\/\/doi.org\/10.1038\/s41523-022-00500-3","journal-title":"npj Breast Cancer"},{"issue":"21","key":"7984_CR7","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.1158\/1078-0432.CCR-24-0149","volume":"30","author":"M Dugo","year":"2024","unstructured":"Dugo M, Huang CS, Egle D et al (2024) The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer. Clin Cancer Res 30(21):4900\u20134909. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0149","journal-title":"Clin Cancer Res"},{"key":"7984_CR8","doi-asserted-by":"crossref","unstructured":"Mittempergher L, Kuilman M, Barcaru A, Nota B (2022) The ImPrint immune signature to identify patients with high-risk early breast cancer who may benefit from PD1 checkpoint inhibition in I-SPY2. In: 40. J Clin Oncol ; :suppl 16; abstr 514.","DOI":"10.1200\/JCO.2022.40.16_suppl.514"},{"issue":"7980","key":"7984_CR9","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41586-023-06498-3","volume":"621","author":"XQ Wang","year":"2023","unstructured":"Wang XQ, Danenberg E, Huang CS et al (2023) Spatial predictors of immunotherapy response in triple-negative breast cancer. Nature 621(7980):868\u2013876. https:\/\/doi.org\/10.1038\/s41586-023-06498-3","journal-title":"Nature"},{"issue":"12","key":"7984_CR10","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","volume":"26","author":"LM Spring","year":"2020","unstructured":"Spring LM, Fell G, Arfe A et al (2020) Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res 26(12):2838\u20132848. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3492","journal-title":"Clin Cancer Res"},{"issue":"2","key":"7984_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S1470-2045(05)01736-5","volume":"6","author":"I Wolf","year":"2005","unstructured":"Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B (2005) Diabetes mellitus and breast cancer. Lancet Oncol 6(2):103\u2013111. https:\/\/doi.org\/10.1016\/S1470-2045(05)01736-5","journal-title":"Lancet Oncol"},{"key":"7984_CR12","doi-asserted-by":"publisher","unstructured":"Ennis CS, Llevenes P, Qiu Y, Dries R, Denis GV (2022) The crosstalk within the breast tumor microenvironment in type II diabetes: Implications for cancer disparities. Front Endocrinol 13\u20132022. https:\/\/www.frontiersin.org\/journals\/endocrinology\/articles\/https:\/\/doi.org\/10.3389\/fendo.2022.1044670","DOI":"10.3389\/fendo.2022.1044670"},{"issue":"4","key":"7984_CR13","doi-asserted-by":"publisher","first-page":"e87489","DOI":"10.1172\/jci.insight.87489","volume":"2","author":"YY Wang","year":"2017","unstructured":"Wang YY, Attan\u00e9 C, Milhas D et al (2017) Mammary adipocytes stimulate breast cancer invasion through metabolic remodeling of tumor cells. JCI Insight 2(4):e87489. https:\/\/doi.org\/10.1172\/jci.insight.87489","journal-title":"JCI Insight"},{"issue":"7","key":"7984_CR14","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1158\/0008-5472.CAN-10-3323","volume":"71","author":"B Dirat","year":"2011","unstructured":"Dirat B, Bochet L, Dabek M et al (2011) Cancer-Associated Adipocytes Exhibit an Activated Phenotype and Contribute to Breast Cancer Invasion. Cancer Res 71(7):2455\u20132465. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-3323","journal-title":"Cancer Res"},{"key":"7984_CR15","doi-asserted-by":"publisher","unstructured":"Miya A, Nakamura A, Miyoshi H et al (2018) Impact of Glucose Loading on Variations in CD4\u2009+\u2009and CD8\u2009+\u2009T Cells in Japanese Participants with or without Type 2 Diabetes. Front Endocrinol 9\u20132018. https:\/\/www.frontiersin.org\/journals\/endocrinology\/articles\/https:\/\/doi.org\/10.3389\/fendo.2018.00081","DOI":"10.3389\/fendo.2018.00081"},{"issue":"7","key":"7984_CR16","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.cell.2020.11.009","volume":"183","author":"AE Ringel","year":"2020","unstructured":"Ringel AE, Drijvers JM, Baker GJ et al (2020) Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity. Cell 183(7):1848\u20131866e26. https:\/\/doi.org\/10.1016\/j.cell.2020.11.009","journal-title":"Cell"},{"issue":"3","key":"7984_CR17","doi-asserted-by":"publisher","first-page":"e20210042","DOI":"10.1084\/jem.20210042","volume":"219","author":"L Dyck","year":"2022","unstructured":"Dyck L, Prendeville H, Raverdeau M et al (2022) Suppressive effects of the obese tumor microenvironment on CD8 T cell infiltration and effector function. J Exp Med 219(3):e20210042. https:\/\/doi.org\/10.1084\/jem.20210042","journal-title":"J Exp Med"},{"issue":"13","key":"7984_CR18","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1200\/JCO.2008.17.5935","volume":"27","author":"TP Srokowski","year":"2009","unstructured":"Srokowski TP, Fang S, Hortobagyi GN, Giordano SH (2009) Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. J Clin Oncol 27(13):2170\u20132176. https:\/\/doi.org\/10.1200\/JCO.2008.17.5935","journal-title":"J Clin Oncol"},{"issue":"9Supplement","key":"7984_CR19","doi-asserted-by":"publisher","first-page":"PS14","DOI":"10.1158\/1538-7445.SABCS23-PS14-02","volume":"84","author":"M Hofherr","year":"2024","unstructured":"Hofherr M, Davis A, January S et al (2024) Abstract PS14-02: Real-world analysis comparing Black and White patients with triple-negative breast cancer receiving therapy per KEYNOTE-522. Cancer Res 84(9Supplement):PS14\u2013PS02. https:\/\/doi.org\/10.1158\/1538-7445.SABCS23-PS14-02","journal-title":"Cancer Res"},{"issue":"16suppl","key":"7984_CR20","doi-asserted-by":"publisher","first-page":"e12663","DOI":"10.1200\/JCO.2024.42.16_suppl.e12663","volume":"42","author":"M Ng\u2019ang\u2019a","year":"2024","unstructured":"Ng\u2019ang\u2019a M, Burdette-Radoux S, Borgen PI et al (2024) Treatment outcomes of the KEYNOTE-522 regimen in an ethnically diverse patient population: A real world experience. JCO 42(16suppl):e12663\u2013e12663. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e12663","journal-title":"JCO"},{"issue":"11","key":"7984_CR21","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/aje\/kwh325","volume":"160","author":"RB Ness","year":"2004","unstructured":"Ness RB, Haggerty CL, Harger G, Ferrell R (2004) Differential distribution of allelic variants in cytokine genes among African Americans and White Americans. Am J Epidemiol 160(11):1033\u20131038. https:\/\/doi.org\/10.1093\/aje\/kwh325","journal-title":"Am J Epidemiol"},{"key":"7984_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/1756-0500-5-248","volume":"5","author":"JM Grunda","year":"2012","unstructured":"Grunda JM, Steg AD, He Q et al (2012) Differential expression of breast cancer-associated genes between stage- and age-matched tumor specimens from African- and Caucasian-American Women diagnosed with breast cancer. BMC Res Notes 5:248. https:\/\/doi.org\/10.1186\/1756-0500-5-248","journal-title":"BMC Res Notes"},{"issue":"5","key":"7984_CR23","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/cncr.26405","volume":"118","author":"LA Field","year":"2012","unstructured":"Field LA, Love B, Deyarmin B, Hooke JA, Shriver CD, Ellsworth RE (2012) Identification of differentially expressed genes in breast tumors from African American compared with Caucasian women. Cancer 118(5):1334\u20131344. https:\/\/doi.org\/10.1002\/cncr.26405","journal-title":"Cancer"},{"issue":"8","key":"7984_CR24","doi-asserted-by":"publisher","first-page":"e72619","DOI":"10.1371\/journal.pone.0072619","volume":"8","author":"Z Gong","year":"2013","unstructured":"Gong Z, Quan L, Yao S et al (2013) Innate immunity pathways and breast cancer Risk in African American and European-American women in the Women\u2019s Circle of Health Study (WCHS). PLoS ONE 8(8):e72619. https:\/\/doi.org\/10.1371\/journal.pone.0072619","journal-title":"PLoS ONE"},{"issue":"3","key":"7984_CR25","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s10549-014-2899-5","volume":"144","author":"CH Kroenke","year":"2014","unstructured":"Kroenke CH, Sweeney C, Kwan ML et al (2014) Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression. Breast Cancer Res Treat 144(3):689\u2013699. https:\/\/doi.org\/10.1007\/s10549-014-2899-5","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"7984_CR26","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/ijc.28458","volume":"134","author":"L Quan","year":"2014","unstructured":"Quan L, Gong Z, Yao S et al (2014) Cytokine and cytokine receptor genes of the adaptive immune response are differentially associated with breast cancer risk in American women of African and European ancestry. Int J Cancer 134(6):1408\u20131421. https:\/\/doi.org\/10.1002\/ijc.28458","journal-title":"Int J Cancer"},{"issue":"3","key":"7984_CR27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10549-016-4062-y","volume":"161","author":"FO Ademuyiwa","year":"2017","unstructured":"Ademuyiwa FO, Tao Y, Luo J, Weilbaecher K, Ma CX (2017) Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians. Breast Cancer Res Treat 161(3):491\u2013499. https:\/\/doi.org\/10.1007\/s10549-016-4062-y","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"7984_CR28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1158\/1055-9965.EPI-17-0434","volume":"27","author":"CC Hong","year":"2018","unstructured":"Hong CC, Sucheston-Campbell LE, Liu S et al (2018) Genetic Variants in Immune-Related Pathways and Breast Cancer Risk in African American Women in the AMBER Consortium. Cancer Epidemiol Biomarkers Prev 27(3):321\u2013330. https:\/\/doi.org\/10.1158\/1055-9965.EPI-17-0434","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"7984_CR29","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1158\/1055-9965.EPI-21-1312","volume":"31","author":"AM Hamilton","year":"2022","unstructured":"Hamilton AM, Hurson AN, Olsson LT et al (2022) The Landscape of Immune Microenvironments in Racially Diverse Breast Cancer Patients. Cancer Epidemiol Biomarkers Prev 31(7):1341\u20131350. https:\/\/doi.org\/10.1158\/1055-9965.EPI-21-1312","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"7984_CR30","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/oncolo\/oyae064","volume":"29","author":"A LeVee","year":"2024","unstructured":"LeVee A, Wong M, Flores S et al (2024) Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis. Oncologist 29(7):566\u2013574. https:\/\/doi.org\/10.1093\/oncolo\/oyae064","journal-title":"Oncologist"},{"issue":"2","key":"7984_CR31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","volume":"10","author":"P Sharma","year":"2024","unstructured":"Sharma P, Stecklein SR, Yoder R et al (2024) Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial. JAMA Oncol 10(2):227\u2013235. https:\/\/doi.org\/10.1001\/jamaoncol.2023.5033","journal-title":"JAMA Oncol"},{"issue":"1","key":"7984_CR32","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41523-022-00448-4","volume":"8","author":"R Yoder","year":"2022","unstructured":"Yoder R, Kimler BF, Staley JM et al (2022) Impact of low versus negative estrogen\/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer. NPJ Breast Cancer 8(1):80. https:\/\/doi.org\/10.1038\/s41523-022-00448-4","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"7984_CR33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41523-021-00308-7","volume":"7","author":"MV Dieci","year":"2021","unstructured":"Dieci MV, Griguolo G, Bottosso M et al (2021) Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant\/adjuvant chemotherapy. NPJ Breast Cancer 7(1):101. https:\/\/doi.org\/10.1038\/s41523-021-00308-7","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"7984_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41523-023-00543-0","volume":"9","author":"L Voorwerk","year":"2023","unstructured":"Voorwerk L, Sanders J, Keusters MS et al (2023) Immune landscape of breast tumors with low and intermediate estrogen receptor expression. NPJ Breast Cancer 9(1):39. https:\/\/doi.org\/10.1038\/s41523-023-00543-0","journal-title":"NPJ Breast Cancer"},{"key":"7984_CR35","doi-asserted-by":"publisher","unstructured":"Acs B, Hartman J, S\u00f6nmez D, Lindman H, Johansson ALV, Fredriksson I (2024) Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort study. Lancet Reg Health \u2013 Europe 40. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100886","DOI":"10.1016\/j.lanepe.2024.100886"},{"issue":"2","key":"7984_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T et al (2024) Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol 35(2):159\u2013182. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.016","journal-title":"Ann Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07984-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07984-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07984-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:30:06Z","timestamp":1784017806000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07984-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7984"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07984-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alexis LeVee: Consultant\/advisory board role for: Incyclix, AstraZeneca.Heather McArthur: Consultant\/advisory board role for: ALX, Amgen, AstraZeneca, BeiGene, Boston Scientific, Bristol-Myers Squibb, Calithera, Celgene, Daiichi-Sankyo, Delcath Systems Inc., Eli Lilly, Genentech\/Roche, Gilead, Immunomedics, Merck, Moderna, Novartis, OBI Pharma, Peregrine, Pfizer\/Seattle Genetics, Puma, Spectrum Pharmaceuticals, Stemline Therapeutics, Syndax Pharmaceuticals, and TapImmune. Research support: Bristol-Myers Squibb; MedImmune, LLC\/AstraZeneca; BTG; and Merck.Joanne Mortimer: Consulting for GE Healthcare. Research support from AstraZeneca, Daiichi Sankyo, and Pfizer.Irene Kang: Consultant for Caris Life Sciences, Gilead, Daiichi-Sankyo, Pfizer, Menarini-Stemline. Research support from Merck.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}